
Novo scraps two heart drug trials, continues ziltivekimab trial for 2027
The story in brief
Novo Nordisk has scrapped two heart drug trials, further limiting growth beyond obesity. However, a trial testing ziltivekimab in heart attack recovery patients will continue, with results expected in early 2027. Data collected includes IP addresses, device identifiers, and location data.